The key findings from this 5-year study of the early-generation Intrepid transapical transcatheter mitral valve replacement system were sustained mitral regurgitation reduction, durable hemodynamic valve performance, and improved functional status among survivors, despite high mortality rates.
This study found that the novel DurAVR transcatheter heart valve demonstrated promising 30-day clinical and echocardiographic outcomes, including a low rate of prosthesis-patient mismatch, in patients with small aortic annuli.
The EuroIntervention team and Editors will be present at PCR London Valves 2025. Don’t miss out on the latest updates from the Journal and the first Alain Cribier Award Ceremony!
A State-of-the-Art on TAVI in biscuspid aortic stenosis; an expert consensus on transcatheter tricuspid valve interventions in patients with transvalvular right ventricular leads; the ACURATE platform discontinuation; coronary cannulation after transfemoral TAVI with the Evolut FX; HALT after TAVI with the SAPIEN Ultra RESILIA; impact of aortic annular size on long-term outcomes and valve durability; the TRICURE first-in-human study; 5-year follow-up of EVOQUE TTVR; and more
This study found a high incidence of asymptomatic and paroxysmal atrial fibrillation following patent foramen ovale closure, with a significant proportion of episodes occurring beyond 30 days post-procedure.